REGENXBIO Inc. (RGNX)Healthcare | Biotechnology | Rockville, United States | NasdaqGS
9.66 USD
+0.29
(3.095%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 9.65 -0.01 (-0.010%) ⇩ (Aug. 28, 2026, 7:56 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:01 a.m. EDT
The long-term investment case is severely compromised by four consecutive years of negative annual returns and a cumulative decline of nearly 34% over the last nine years. This persistent multi-year downtrend suggests the market has permanently reassessed the business quality, rendering any current valuation metrics irrelevant as a margin of safety. While the company recently raised capital via a public offering, the immediate dilution combined with negative free cash flow and a lack of dividend support creates a precarious environment for shareholders. On the short end, the picture is mixed; while the statistical forecast offers no directional edge, options flow reveals a tension between defensive hedging and speculative bets on a turnaround. Given the structural deterioration evident in the price history and the absence of sustainable profitability, the security warrants avoidance. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.525905 |
| AutoETS | 0.525907 |
| MSTL | 0.569941 |
| AutoTheta | 0.677709 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 1.02 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.685 |
| Excess Kurtosis | 0.43 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 349.003 |
| Revenue per Share | 3.344 |
| Market Cap | 637,687,424 |
| Forward P/E | -3.22 |
| Beta | 0.94 |
| Profit Margins | -112.58% |
| Website | https://www.regenxbio.com |
As of Aug. 22, 2026, 4:01 a.m. EDT: Speculators are positioning defensively with heavy open interest in out-of-the-money puts (strikes 9.0 and 10.0) across multiple expirations, indicating a fear of further downside. However, there is significant new volume flowing into out-of-the-money calls (strikes 12.0 and 16.0), suggesting a speculative bet on a potential catalyst-driven rally despite the bearish backdrop.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.05921054 |
| Address1 | 9,804 Medical Center Drive |
| All Time High | 85.1 |
| All Time Low | 5.035 |
| Ask | 11.84 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 1,579,270 |
| Average Daily Volume3 Month | 1,982,374 |
| Average Volume | 1,982,374 |
| Average Volume10Days | 1,579,270 |
| Beta | 0.938 |
| Bid | 9.57 |
| Bid Size | 1 |
| Board Risk | 8 |
| Book Value | 1.325 |
| City | Rockville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 9.66 |
| Current Ratio | 2.858 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 10.1 |
| Day Low | 9.212 |
| Debt To Equity | 349.003 |
| Display Name | REGENXBIO |
| Earnings Call Timestamp End | 1,786,017,600 |
| Earnings Call Timestamp Start | 1,786,017,600 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -148,776,992 |
| Ebitda Margins | -0.85267997 |
| Enterprise To Ebitda | -5.26 |
| Enterprise To Revenue | 4.485 |
| Enterprise Value | 782,632,448 |
| Eps Current Year | -3.5185 |
| Eps Forward | -3.00312 |
| Eps Trailing Twelve Months | -3.78 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 10.9618 |
| Fifty Day Average Change | -1.3017998 |
| Fifty Day Average Change Percent | -0.11875785 |
| Fifty Two Week Change Percent | 5.921054 |
| Fifty Two Week High | 16.19 |
| Fifty Two Week High Change | -6.5300007 |
| Fifty Two Week High Change Percent | -0.40333542 |
| Fifty Two Week Low | 5.455 |
| Fifty Two Week Low Change | 4.205 |
| Fifty Two Week Low Change Percent | 0.77085245 |
| Fifty Two Week Range | 5.455 - 16.19 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,442,496,600,000 |
| Float Shares | 57,343,019 |
| Forward Eps | -3.00312 |
| Forward P E | -3.2166548 |
| Free Cashflow | -184,263,504 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 371 |
| Fullday Change | 0.29 |
| Fullday Change Percent | 3.09498 |
| Fullday Price | 9.65 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | -0.44946998 |
| Gross Profits | -78,424,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06266 |
| Held Percent Institutions | 0.65535 |
| Implied Shares Outstanding | 66,013,192 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. |
| Long Name | REGENXBIO Inc. |
| Market | us_market |
| Market Cap | 637,687,424 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_130641748 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -196,432,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 618,543,609 |
| Number Of Analyst Opinions | 11 |
| Open | 10.0 |
| Operating Cashflow | -246,674,000 |
| Operating Margins | 0.27091 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 240 552 8181 |
| Post Market Change | -0.010000229 |
| Post Market Change Percent | -0.10352204 |
| Post Market Price | 9.65 |
| Post Market Time | 1,787,961,397 |
| Previous Close | 9.37 |
| Price Eps Current Year | -2.745488 |
| Price Hint | 2 |
| Price To Book | 7.2905655 |
| Price To Sales Trailing12 Months | 3.6547463 |
| Profit Margins | -1.1258 |
| Quick Ratio | 2.701 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.63636 |
| Region | US |
| Regular Market Change | 0.29 |
| Regular Market Change Percent | 3.09498 |
| Regular Market Day High | 10.1 |
| Regular Market Day Low | 9.212 |
| Regular Market Day Range | 9.212 - 10.1 |
| Regular Market Open | 10.0 |
| Regular Market Previous Close | 9.37 |
| Regular Market Price | 9.66 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 1,752,502 |
| Return On Assets | -0.21204 |
| Return On Equity | -1.3763299 |
| Revenue Growth | 4.057 |
| Revenue Per Share | 3.344 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 66,013,192 |
| Shares Percent Shares Out | 0.1242 |
| Shares Short | 8,197,515 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 8,626,772 |
| Short Name | REGENXBIO Inc. |
| Short Percent Of Float | 0.1314 |
| Short Ratio | 5.32 |
| Source Interval | 15 |
| State | MD |
| Symbol | RGNX |
| Target High Price | 50.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 23.72727 |
| Target Median Price | 19.0 |
| Total Cash | 105,517,000 |
| Total Cash Per Share | 1.598 |
| Total Debt | 250,462,000 |
| Total Revenue | 174,482,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.78 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.38145 |
| Two Hundred Day Average Change | -0.72144985 |
| Two Hundred Day Average Change Percent | -0.069494136 |
| Type Disp | Equity |
| Volume | 1,752,502 |
| Website | https://www.regenxbio.com |
| Zip | 20,850 |